Fig. 1: Sample collection scheme. | Nature Medicine

Fig. 1: Sample collection scheme.

From: Trastuzumab deruxtecan in HER2-positive advanced gastric cancer: exploratory biomarker analysis of the randomized, phase 2 DESTINY-Gastric01 trial

Fig. 1

Exploratory biomarker data were collected from primary and exploratory cohorts at baseline and EoT. Tumor tissue was selected for HER2 status and RNA-seq, and liquid biopsy was used to examine plasma and serum biomarkers. Plasma analysis examined ctDNA and serum biomarkers included HER2ECD. There were 91 patients in the HER2 IHC 3+ cohort and 28 in the HER2 IHC 2+/ISH+ cohort. aChanges in plasma HER2 amplification were categorized as either baseline (alterations detected at baseline) or acquired (alterations detected only in EoT samples). bGene alterations concomitant with T-DXd resistance. Amp., amplification; CGEP, comprehensive gene expression profile.

Back to article page